On the public citation graph
Gastrointestinal and Skin Safety Evaluation of Pirfenidone Versus Nintedanib: An Analysis of Real-World Pharmacovigilance and Randomized Controlled Trials
0 signed · 28 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/s10753-018-0871-yopenalex-extracted
Pirfenidone Ointment Modulates the Burn Wound Bed in C57BL/6 Mice by Suppressing Inflammatory Responses
inferredcites →https://doi.org/10.1007/s12325-014-0112-1openalex-extracted
Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
inferredcites →https://doi.org/10.1016/j.ejphar.2008.06.046openalex-extracted
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
inferredcites →https://doi.org/10.1016/j.ejphar.2014.10.025openalex-extracted
Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi
inferredcites →https://doi.org/10.1016/j.ejps.2014.02.014openalex-extracted
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts
inferredcites →https://doi.org/10.1016/j.jphotobiol.2013.01.010openalex-extracted
Photosafety assessments on pirfenidone: Photochemical, photobiological, and pharmacokinetic characterization
inferredcites →https://doi.org/10.1016/j.phrs.2021.105635openalex-extracted
New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.1016/j.pupt.2015.03.007openalex-extracted
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways
inferredcites →https://doi.org/10.1016/s2213-2600(20)30225-3openalex-extracted
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
inferredcites →https://doi.org/10.1016/s2665-9913(22)00215-6openalex-extracted
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials
inferredcites →https://doi.org/10.1080/14656566.2018.1425681openalex-extracted
Nintedanib for the treatment of idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.1097/mcp.0000000000000091openalex-extracted
IPF clinical trial design and endpoints
inferredcites →https://doi.org/10.1111/1346-8138.13009openalex-extracted
Pirfenidone‐induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.1158/0008-5472.can-07-6307openalex-extracted
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
inferredcites →https://doi.org/10.1164/rccm.200211-1311ocopenalex-extracted
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
inferredcites →https://doi.org/10.1164/rccm.201403-0566ocopenalex-extracted
Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences
inferredcites →https://doi.org/10.1177/1060028020964451openalex-extracted
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
inferredcites →https://doi.org/10.1177/17534666231181537openalex-extracted
Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
inferredcites →https://doi.org/10.1183/09031936.00185114openalex-extracted
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
inferredcites →https://doi.org/10.1183/23120541.00084-2018openalex-extracted
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
inferredcites →https://doi.org/10.1186/1465-9921-14-s1-s5openalex-extracted
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.1186/s40248-018-0158-zopenalex-extracted
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.1248/yakushi.15-00224-5openalex-extracted
Analysis of Spontaneously Reported Adverse Events
inferredcites →https://doi.org/10.3390/ijms22073765openalex-extracted
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
inferredcites →https://doi.org/10.3390/pharmaceutics14040813openalex-extracted
Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside
inferredcites →https://doi.org/10.4103/ejcdt.ejcdt_140_19openalex-extracted
Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
inferredcites →https://doi.org/10.7150/ijms.6048openalex-extracted
Data Mining of the Public Version of the FDA Adverse Event Reporting System
inferredcites →https://doi.org/10.4081/mrm.2018.215openalex-snapshot
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.